143P - Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)
| Autor: | Martin-Liberal, J., Pagliuca, F., Hierro, C., Viaplana, C., Muñoz Couselo, E., Capdevila, J., Matos, I., Fariñas Madrid, L., Zamora, E., Braña Garcia, I., Elez Fernandez, E., Ochoa De Olza Amat, M., Azaro, A., Alsina, M., Vieito Villar, M., Fasani, R., Tabernero, J., Garralda, E., Dienstmann, R., Nuciforo, P.G. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29 Supplement 8 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|